You are here

Paxlovid

Covid Drug Paxlovid Now Less Effective Than In Early Trials—But It’s Still Great At Preventing Death

Covid Drug Paxlovid Now Less Effective Than In Early Trials—But It’s Still Great At Preventing Death

Forbes

clinical trials

Flag link:

US to test Paxlovid as long COVID-19 therapy

US to test Paxlovid as long COVID-19 therapy

Beckers Hospital Review

clinical trials

Flag link:

Ex-Pfizer employee charged with insider trading over Covid treatment

Ex-Pfizer employee charged with insider trading over Covid treatment

FT.com

Flag link:

FDA grants full approval to Pfizer Covid treatment Paxlovid for high-risk adults

FDA grants full approval to Pfizer Covid treatment Paxlovid for high-risk adults

CNBC

Flag link:

Pfizer reports strong Q1 earnings, including $18.3B in revenues

Pfizer reports strong Q1 earnings, including $18.3B in revenues

Medical Marketing and Media

Flag link:

New Yale study evaluates PAXLOVID's use in Long COVID recovery

New Yale study evaluates PAXLOVID's use in Long COVID recovery

Drugs.com

clinical trials

Flag link:

FDA adcomm votes in favor of Pfizer's Covid-19 pill Paxlovid

FDA adcomm votes in favor of Pfizer's Covid-19 pill Paxlovid

Endpoints

Flag link:

FDA staff report says data shows Pfizer’s Covid treatment Paxlovid is effective in high-risk adults

FDA staff report says data shows Pfizer’s Covid treatment Paxlovid is effective in high-risk adults

CNBC

Flag link:

This Week at FDA: Restructuring at inspections office, new guidances and staff, and more

This Week at FDA: Restructuring at inspections office, new guidances and staff, and more

RAPS.org

regulatory inspections

Flag link:

FDA axes requirement for positive Covid test before Paxlovid use

FDA axes requirement for positive Covid test before Paxlovid use

Endpoints

Flag link:

Pfizer’s full-year revenues grow 23%, top $100B

Pfizer’s full-year revenues grow 23%, top $100B

Medical Marketing and Media

Flag link:

AbbVie, Novartis and more win national coverage in China even as Pfizer's Paxlovid gets left out

AbbVie, Novartis and more win national coverage in China even as Pfizer's Paxlovid gets left out

Fierce Pharma

Flag link:

Pfizer pledges to sell all of its products at cost to poor countries

Pfizer pledges to sell all of its products at cost to poor countries

Fierce Pharma

Flag link:

Pfizer's search for Paxlovid's COVID-busting sibling leads to low-profile antiviral biotech

Pfizer's search for Paxlovid's COVID-busting sibling leads to low-profile antiviral biotech

Fierce Biotech

Flag link:

Researchers Are Studying Whether Paxlovid Can Treat Long COVID

Researchers Are Studying Whether Paxlovid Can Treat Long COVID

Time

Flag link:

FDA chief stands by Paxlovid nod amid discussion on 'rebound' cases

FDA chief stands by Paxlovid nod amid discussion on 'rebound' cases

Fierce Pharma

Flag link:

Pfizer to supply 6 million Paxlovid treatments to Global Fund

Pfizer to supply 6 million Paxlovid treatments to Global Fund

Axios

Flag link:

Pfizer's Paxlovid only helped seniors avoid hospitalization and death, new NEJM study finds

Pfizer's Paxlovid only helped seniors avoid hospitalization and death, new NEJM study finds

Endpoints

Flag link:

Pfizer sales of COVID-19 vaccine, pill beat forecasts as company prepares for future waves

Pfizer sales of COVID-19 vaccine, pill beat forecasts as company prepares for future waves

BioPharma Dive

Flag link:

Pfizer's Paxlovid sales will top at $30B this year then fall over time: analysts

Pfizer's Paxlovid sales will top at $30B this year then fall over time: analysts

Fierce Pharma

Flag link:

Pages